Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2014

Open Access 01-12-2014 | Review

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment

Authors: Yan-Yang Wang, Hong Zhe, Ren Zhao

Published in: Molecular Cancer | Issue 1/2014

Login to get access

Abstract

Solid cancer remains a major cause of death in the world. As limited treatment options are currently available to patients with solid cancer, novel preventive control and effective therapeutic approaches are considered to be reasonable and decisive measures to combat this disease. The plant-derived triterpenoids, commonly used for medicinal purposes in many Asian countries, poses various pharmacological properties. A large number of triterpenoids exhibit cytotoxicity against a variety of cancer cells, and cancer preventive, as well as anticancer efficacy in preclinical animal models. To improve antitumor activity, some synthetic triterpenoid derivatives have been synthesized, including cyano-3,12-dioxooleana-1,9(11)- dien-28-oic (CDDO), its methyl ester (CDDO-Me), and imidazolide (CDDO-Im) derivatives. In this review, we will critically examine the current preclinical evidences of cancer preventive and therapeutic activity about one of the synthetic triterpenoids, CDDO-Me. Both in vitro and in vivo effects of this agent and related molecular mechanisms are presented.
Literature
1.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9CrossRefPubMed
2.
Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013CrossRefPubMed
3.
Patlolla JM, Rao CV: Triterpenoids for cancer prevention and treatment: current status and future prospects. Curr Pharm Biotechnol. 2012, 13: 147-155. 10.2174/138920112798868719CrossRefPubMed
4.
Petronelli A, Pannitteri G, Testa U: Triterpenoids as new promising anticancer drugs. Anticancer Drugs. 2009, 20: 880-892. 10.1097/CAD.0b013e328330fd90CrossRefPubMed
5.
Liby KT, Sporn MB: Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease. Pharmacol Rev. 2012, 64: 972-1003. 10.1124/pr.111.004846PubMedCentralCrossRefPubMed
6.
Yadav VR, Prasad S, Sung B, Kannappan R, Aggarwal BB: Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer. Toxins (Basel). 2010, 2: 2428-2466. 10.3390/toxins2102428CrossRef
7.
Liby KT, Yore MM, Sporn MB: Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer. 2007, 7: 357-369. 10.1038/nrc2129CrossRefPubMed
8.
Ovesná Z, Vachálková A, Horváthová K, Tóthová D: Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma. 2004, 51: 327-333.PubMed
9.
Bishayee A, Ahmed S, Brankov N, Perloff M: Triterpenoids as potential agents for the chemoprevention and therapy of breast cancer. Front Biosci. 2011, 16: 980-996. 10.2741/3730.CrossRef
10.
Setzer WN, Setzer MC: Plant-derived triterpenoids as potential antineoplastic agents. Mini Rev Med Chem. 2003, 3: 540-556. 10.2174/1389557033487854CrossRefPubMed
11.
Laszczyk MN: Pentacyclic triterpenes of the lupane, oleanane and ursane group as tools in cancer therapy. Planta Med. 2009, 75: 1549-1560. 10.1055/s-0029-1186102CrossRefPubMed
12.
Murakami A, Ohigashi H: Targeting NOX, INOS and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer. 2007, 121: 2357-2363. 10.1002/ijc.23161CrossRefPubMed
13.
Kundu JK, Surh YJ: Inflammation: gearing the journey to cancer. Mutat Res. 2008, 659: 15-30. 10.1016/j.mrrev.2008.03.002CrossRefPubMed
14.
Suh N, Wang Y, Honda T, Gribble GW, Dmitrovsky E, Hickey WF, Maue RA, Place AE, Porter DM, Spinella MJ, Williams CR, Wu G, Dannenberg AJ, Flanders KC, Letterio JJ, Mangelsdorf DJ, Nathan CF, Nguyen L, Porter WW, Ren RF, Roberts AB, Roche NS, Subbaramaiah K, Sporn MB: A novel synthetic oleanane triterpenoid, 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid, with potent differentiating, antiproliferative, and anti-inflammatory activity. Cancer Res. 1999, 59: 336-341.PubMed
15.
Deeb D, Gao X, Dulchavsky SA, Gautam SC: CDDO-Me inhibits proliferation, induces apoptosis, down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated antiapoptotic and proangiogenic proteins in TRAMP prostate cancer cells. J Exp Ther Oncol. 2008, 7: 31-39.PubMed
16.
Liby K, Royce DB, Williams CR, Risingsong R, Yore MM, Honda T, Gribble GW, Dmitrovsky E, Sporn TA, Sporn MB: The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. Cancer Res. 2007, 67: 2414-2419. 10.1158/0008-5472.CAN-06-4534CrossRefPubMed
17.
Liby K, Risingsong R, Royce DB, Williams CR, Yore MM, Honda T, Gribble GW, Lamph WW, Vannini N, Sogno I, Albini A, Sporn MB: Prevention and treatment of experimental estrogen receptor-negative mammary carcinogenesis by the synthetic triterpenoid CDDO-methyl Ester and the rexinoid LG100268. Clin Cancer Res. 2008, 14: 4556-4563. 10.1158/1078-0432.CCR-08-0040CrossRefPubMed
18.
Liby KT, Royce DB, Risingsong R, Williams CR, Maitra A, Hruban RH, Sporn MB: Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer PrevRes (Phila). 2010, 3: 1427-1434. 10.1158/1940-6207.CAPR-10-0197.CrossRef
19.
Tran K, Risingsong R, Royce D, Williams CR, Sporn MB, Liby K: The synthetic triterpenoid CDDO-methyl ester delays estrogen receptor-negative mammary carcinogenesis in polyoma middle T mice. Cancer Prev Res (Phila). 2012, 5: 726-734. 10.1158/1940-6207.CAPR-11-0404CrossRef
20.
Kim EH, Deng C, Sporn MB, Royce DB, Risingsong R, Williams CR, Liby KT: CDDO-methyl ester delays breast cancer development in BRCA1-mutated mice. Cancer Prev Res (Phila). 2012, 5: 89-97. 10.1158/1940-6207.CAPR-11-0359CrossRef
21.
Deeb D, Gao X, Liu Y, Jiang D, Divine GW, Arbab AS, Dulchavsky SA, Gautam SC: Synthetic triterpenoid CDDO prevents the progression and metastasis of prostate cancer in TRAMP mice by inhibiting survival signaling. Carcinogenesis. 2011, 32: 757-764. 10.1093/carcin/bgr030PubMedCentralCrossRefPubMed
22.
Gao X, Deeb D, Liu Y, Arbab AS, Divine GW, Dulchavsky SA, Gautam SC: Prevention of prostate cancer with oleanane synthetic triterpenoid CDDO-Me in the TRAMP mouse model of prostate cancer. Cancers (Basel). 2011, 3: 3353-3369. 10.3390/cancers3033353CrossRef
23.
Liu Y, Gao X, Deeb D, Arbab AS, Gautam SC: Telomerase reverse transcriptase (TERT) is a therapeutic target of oleanane triterpenoid CDDO-Me in prostate cancer. Molecules. 2012, 17: 14795-14809. 10.3390/molecules171214795PubMedCentralCrossRefPubMed
24.
25.
Ben-Neriah Y, Karin M: Inflammation meets cancer, with NF-κB as the match maker. Nat Immunol. 2011, 12: 715-723. 10.1038/ni.2060CrossRefPubMed
26.
Deeb D, Gao X, Dulchavsky SA, Gautam SC: CDDO-me induces apoptosis and inhibits Akt, mTOR and NF-kappaB signaling proteins in prostate cancer cells. Anticancer Res. 2007, 27: 3035-3044.PubMed
27.
Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009, 9: 550-562. 10.1038/nrc2664CrossRefPubMed
28.
Bunney TD, Katan M: Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer. 2010, 10: 342-352. 10.1038/nrc2842CrossRefPubMed
29.
30.
Deeb D, Gao X, Jiang H, Dulchavsky SA, Gautam SC: Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells by independently targeting pro-survival Akt and mTOR. Prostate. 2009, 69: 851-860. 10.1002/pros.20937CrossRefPubMed
31.
Deeb D, Gao X, Jiang H, Janic B, Arbab AS, Rojanasakul Y, Dulchavsky SA, Gautam SC: Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism. Biochem Pharmacol. 2010, 79: 350-360. 10.1016/j.bcp.2009.09.006PubMedCentralCrossRefPubMed
32.
Deeb D, Gao X, Arbab AS, Barton K, Dulchavsky SA, Gautam SC: CDDO-Me: a novel synthetic triterpenoid for the treatment of pancreatic cancer. Cancers (Basel). 2010, 2: 1779-1793. 10.3390/cancers2041779CrossRef
33.
Deeb D, Gao X, Liu YB, Gautam SC: Inhibition of cell proliferation and induction of apoptosis by CDDO-Me in pancreatic cancer cells is ROS-dependent. J Exp Ther Oncol. 2012, 10: 51-64.PubMedCentralPubMed
34.
Gao X, Deeb D, Hao J, Liu Y, Arbab AS, Dulchavsky SA, Gautam SC: Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells. Anticancer Res. 2010, 30: 785-792.PubMedCentralPubMed
35.
Gao X, Deeb D, Liu P, Liu Y, Arbab-Ali S, Dulchavsky SA, Gautam SC: Role of reactive oxygen species (ROS) in CDDO-Me-mediated growth inhibition and apoptosis in colorectal cancer cells. J Exp Ther Oncol. 2011, 9: 119-127.PubMedCentralPubMed
36.
Gao X, Liu Y, Deeb D, Arbab AS, Guo AM, Dulchavsky SA, Gautam SC: Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling. Anticancer Res. 2011, 31: 3673-3681.PubMedCentralPubMed
37.
Gao X, Liu Y, Deeb D, Liu P, Liu A, Arbab AS, Gautam SC: ROS mediate proapoptotic and antisurvival activity of oleanane triterpenoid CDDO-Me in ovarian cancer cells. Anticancer Res. 2013, 33: 215-221.PubMedCentralPubMed
38.
Gao X, Deeb D, Jiang H, Liu Y, Dulchavsky SA, Gautam SC: Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling. J Neurooncol. 2007, 84: 147-157. 10.1007/s11060-007-9364-9CrossRefPubMed
39.
Yu H, Pardoll D, Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 2009, 9: 798-809. 10.1038/nrc2734CrossRefPubMed
40.
Grivennikov SI, Karin M: Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21: 11-19. 10.1016/j.cytogfr.2009.11.005PubMedCentralCrossRefPubMed
41.
Ahmad R, Raina D, Meyer C, Kufe D: Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)– > signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3. Cancer Res. 2008, 68: 2920-2926. 10.1158/0008-5472.CAN-07-3036PubMedCentralCrossRefPubMed
42.
Duan Z, Ames RY, Ryan M, Hornicek FJ, Mankin H, Seiden MV: CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells. Cancer Chemother Pharmacol. 2009, 63: 681-689. 10.1007/s00280-008-0785-8PubMedCentralCrossRefPubMed
43.
Ryu K, Susa M, Choy E, Yang C, Hornicek FJ, Mankin HJ, Duan Z: Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway. BMC Cancer. 2010, 10: 187- 10.1186/1471-2407-10-187PubMedCentralCrossRefPubMed
44.
45.
Kim KB, Lotan R, Yue P, Sporn MB, Suh N, Gribble GW, Honda T, Wu GS, Hong WK, Sun SY: Identification of a novel synthetic triterpenoid, methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate, that potently induces caspase-mediated apoptosis in human lung cancer cells. Mol Cancer Ther. 2002, 1: 177-184.CrossRefPubMed
46.
Konopleva M, Tsao T, Ruvolo P, Stiouf I, Estrov Z, Leysath CE, Zhao S, Harris D, Chang S, Jackson CE, Munsell M, Suh N, Gribble G, Honda T, May WS, Sporn MB, Andreeff M: Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia. Blood. 2002, 99: 326-335. 10.1182/blood.V99.1.326CrossRefPubMed
47.
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY: c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells. Cancer Res. 2004, 64: 7570-7578. 10.1158/0008-5472.CAN-04-1238CrossRefPubMed
48.
Zou W, Yue P, Khuri FR, Sun SY: Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation. Cancer Res. 2008, 68: 7484-7492. 10.1158/0008-5472.CAN-08-1318PubMedCentralCrossRefPubMed
49.
Zou W, Chen S, Liu X, Yue P, Sporn MB, Khuri FR, Sun SY: c-FLIP downregulation contributes to apoptosis induction by the novel synthetic triterpenoid methyl-2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate (CDDO-Me) in human lung cancer cells. Cancer Biol Ther. 2007, 6: 1614-1620. 10.4161/cbt.6.10.4763CrossRefPubMed
50.
51.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL, Shay JW: Specific association of human telomerase activity with immortal cells and cancer. Science. 1994, 266: 2011-2015. 10.1126/science.7605428CrossRefPubMed
52.
Shay JW, Bacchetti S: A survey of telomerase activity in human cancer. Eur J Cancer. 1997, 33: 787-791. 10.1016/S0959-8049(97)00062-2CrossRefPubMed
53.
Cech TR: Beginning to understand the end of the chromosome. Cell. 2004, 116: 273-279. 10.1016/S0092-8674(04)00038-8CrossRefPubMed
54.
Deeb D, Gao X, Liu Y, Kim SH, Pindolia KR, Arbab AS, Gautam SC: Inhibition of cell proliferation and induction of apoptosis by oleanane triterpenoid (CDDO-Me) in pancreatic cancer cells is associated with the suppression of hTERT gene expression and its telomerase activity. Biochem Biophys Res Commun. 2012, 422: 561-567. 10.1016/j.bbrc.2012.05.024PubMedCentralCrossRefPubMed
55.
Deeb D, Gao X, Liu Y, Varma NR, Arbab AS, Gautam SC: Inhibition of telomerase activity by oleanane triterpenoid CDDO-Me in pancreatic cancer cells is ROS-dependent. Molecules. 2013, 18: 3250-3265. 10.3390/molecules18033250PubMedCentralCrossRefPubMed
56.
Nagaraj S, Youn JI, Weber H, Iclozan C, Lu L, Cotter MJ, Meyer C, Becerra CR, Fishman M, Antonia S, Sporn MB, Liby KT, Rawal B, Lee JH, Gabrilovich DI: Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res. 2010, 16: 1812-1823. 10.1158/1078-0432.CCR-09-3272PubMedCentralCrossRefPubMed
57.
Ostrand-Rosenberg S: Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother. 2010, 59: 1593-1600. 10.1007/s00262-010-0855-8PubMedCentralCrossRefPubMed
58.
Youn JI, Gabrilovich DI: The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur J Immunol. 2010, 40: 2969-2975. 10.1002/eji.201040895PubMedCentralCrossRefPubMed
59.
Jutooru I, Chadalapaka G, Abdelrahim M, Basha MR, Samudio I, Konopleva M, Andreeff M, Safe S: Methyl 2-cyano-3, 12-dioxooleana-1, 9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a. Mol Pharmacol. 2010, 78: 226-236. 10.1124/mol.110.064451PubMedCentralCrossRefPubMed
60.
Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M: The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res. 2007, 67: 4210-4218. 10.1158/0008-5472.CAN-06-3629CrossRefPubMed
61.
Hong DS, Kurzrock R, Supko JG, He X, Naing A, Wheler J, Lawrence D, Eder JP, Meyer CJ, Ferguson DA, Mier J, Konopleva M, Konoplev S, Andreeff M, Kufe D, Lazarus H, Shapiro GI, Dezube BJ: A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012, 18: 3396-3406. 10.1158/1078-0432.CCR-11-2703PubMedCentralCrossRefPubMed
Metadata
Title
Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
Authors
Yan-Yang Wang
Hong Zhe
Ren Zhao
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-13-30

Other articles of this Issue 1/2014

Molecular Cancer 1/2014 Go to the issue

Research

Induction of integrin α2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture

Research

Divergent effects of muscarinic receptor subtype gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia

Research

Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer

Research

Gold (I) N-heterocyclic carbene complex inhibits mouse melanoma growth by p53 upregulation

Research

miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer

Research

Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits